Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Keratin 16 pseudogene 6 (KRT16P6, also referred to as lncKRT16P6) encodes a long non-coding RNA (lncRNA) rather than a protein. Recent research identified lncKRT16P6 as a cancer-associated lncRNA that promotes the progression of tongue squamous cell carcinoma by acting as a sponge for microRNA miR‑3180 and regulating the expression of the chromatin modifier GATAD2A. It does not encode a functional keratin protein, distinguishing it from functional KRT16, and instead may have roles in the regulation of gene expression and cellular pathways via RNA-mediated mechanisms. Pseudogenes like KRT16P6 are often the remnants of ancestral genes and can acquire regulatory roles, especially as lncRNAs.
Not applicable for drugs, but mechanistically, lncKRT16P6 acts by “sponging” miR-3180 and regulating GATAD2A expression (affecting gene expression regulatory networks)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Keratin 16 pseudogene 6 (KRT16P6).